DataM resources that are widely useful for your reference. We have curated special links for you to browse through

The generalized myasthenia gravis treatment landscape is evolving with the FDA approval of KLYGEFA and continued development of complement inhibitors, FcRn antagonists, B-cell therapies and CAR-T programs. Explore approved drugs, clinical-stage assets, pharmaceutical companies, competitive positioning and the global gMG treatment market outlook through 2035.
November 17, 2026

Retatrutide is generating significant commercial attention before regulatory approval, with illegal online sellers, counterfeit products and unapproved peptide markets creating a complex pharmaceutical commercialization environment. This article examines how the pre-approval retatrutide black market could influence future drug launch strategies, patient expectations, pricing perceptions, brand protection and market access.
November 12, 2026

Biotech funding is rising in 2026, but startup survival remains increasingly difficult. Despite $12.6 billion in biopharma venture capital funding during H1 2026, healthcare financing deal counts have declined, with capital concentrating in fewer companies.
November 12, 2026

Keytruda's approaching U.S. patent cliff is creating one of the most significant biosimilar commercialization opportunities in oncology. With Formycon and Zydus advancing FYB206 through FDA review, the competitive landscape is shifting from regulatory development toward market access, institutional contracting and provider adoption.
November 12, 2026

The positive Phase 3 INTerpath-001 results reported by Merck and Moderna in August 2026 mark an important milestone for personalized mRNA cancer vaccines. However, translating clinical success into commercial adoption requires a manufacturing and logistics model capable of delivering thousands of individualized therapies reliably and cost-effectively.
November 12, 2026